# Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

> **NCT04922554** · PHASE2 · COMPLETED · sponsor: **Paratek Pharmaceuticals Inc** · enrollment: 66 (actual)

## Conditions studied

- Mycobacterium Infections, Nontuberculous
- Mycobacterium Abscessus Infection
- Nontuberculous Mycobacterial Lung Disease
- Nontuberculous Mycobacterial Pulmonary Infection

## Interventions

- **DRUG:** Omadacycline Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04922554
- **Lead sponsor:** Paratek Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-15
- **Primary completion:** 2024-06-17
- **Final completion:** 2024-07-17
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04922554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04922554, "Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04922554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*